×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SLNO – soleno therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SLNO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/17
10:00 pm
slno
Soleno Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Soleno Therapeutics, Inc. - SLNO
Neutral
Report
Soleno Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Soleno Therapeutics, Inc. - SLNO
4/17
05:02 pm
slno
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit
Low
Report
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit
4/17
03:31 pm
slno
Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Low
Report
Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
4/17
11:54 am
slno
Bragar Eagel & Squire, P.C. Urges Soleno Therapeutics, Inc. Investors with Significant Losses to Contact the Firm Before May 5th Lead Plaintiff Deadline
Low
Report
Bragar Eagel & Squire, P.C. Urges Soleno Therapeutics, Inc. Investors with Significant Losses to Contact the Firm Before May 5th Lead Plaintiff Deadline
4/17
09:11 am
slno
SLNO SHAREHOLDER NOTICE: Hagens Berman Alerts Soleno (SLNO) Investors to Pending Securities Fraud Class Action and Upcoming May 5th Lead Plaintiff Deadline
Low
Report
SLNO SHAREHOLDER NOTICE: Hagens Berman Alerts Soleno (SLNO) Investors to Pending Securities Fraud Class Action and Upcoming May 5th Lead Plaintiff Deadline
4/17
09:00 am
slno
SLNO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Soleno Therapeutics, Inc. Securities Lawsuit — The Gross Law Firm
Low
Report
SLNO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Soleno Therapeutics, Inc. Securities Lawsuit — The Gross Law Firm
4/17
07:03 am
slno
Soleno Therapeutics (SLNO) was given a new $53.00 price target by Wells Fargo & Company.
Low
Report
Soleno Therapeutics (SLNO) was given a new $53.00 price target by Wells Fargo & Company.
4/16
12:00 pm
slno
Bronstein, Gewirtz & Grossman LLC Urges Soleno Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Low
Report
Bronstein, Gewirtz & Grossman LLC Urges Soleno Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Date
Time
Symbol
Company Name
Action
%Chg
2/25/2026
04:01 pm
slno
soleno therapeutics, inc.
BEAT
Report
-7.1%
soleno therapeutics, inc.
11/4/2025
04:01 pm
slno
soleno therapeutics, inc.
BEAT
Report
-26.4%
soleno therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/7
06:59 am
slno
Form 8-K SOLENO THERAPEUTICS INC For: Apr 07
Low
Report
Form 8-K SOLENO THERAPEUTICS INC For: Apr 07
4/7
06:01 am
slno
Form SC TO-C SOLENO THERAPEUTICS INC Filed by: NEUROCRINE BIOSCIENCES INC
Low
Report
Form SC TO-C SOLENO THERAPEUTICS INC Filed by: NEUROCRINE BIOSCIENCES INC
4/6
05:18 pm
slno
Form SC14D9C SOLENO THERAPEUTICS INC Filed by: SOLENO THERAPEUTICS INC
Low
Report
Form SC14D9C SOLENO THERAPEUTICS INC Filed by: SOLENO THERAPEUTICS INC
4/6
05:08 pm
slno
Form SC TO-C SOLENO THERAPEUTICS INC Filed by: NEUROCRINE BIOSCIENCES INC
Low
Report
Form SC TO-C SOLENO THERAPEUTICS INC Filed by: NEUROCRINE BIOSCIENCES INC
4/6
07:47 am
slno
Form 8-K SOLENO THERAPEUTICS INC For: Apr 05
Low
Report
Form 8-K SOLENO THERAPEUTICS INC For: Apr 05
4/6
07:39 am
slno
Form SC TO-C SOLENO THERAPEUTICS INC Filed by: NEUROCRINE BIOSCIENCES INC
Low
Report
Form SC TO-C SOLENO THERAPEUTICS INC Filed by: NEUROCRINE BIOSCIENCES INC
3/31
08:17 pm
slno
Form 4 SOLENO THERAPEUTICS INC For: Mar 27 Filed by: Manning Meredith
Medium
Report
Form 4 SOLENO THERAPEUTICS INC For: Mar 27 Filed by: Manning Meredith
3/31
08:16 pm
slno
Form 4 SOLENO THERAPEUTICS INC For: Mar 27 Filed by: Huang Michael F.
Medium
Report
Form 4 SOLENO THERAPEUTICS INC For: Mar 27 Filed by: Huang Michael F.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/23
Soleno Therapeutics Announces Pricing of $13.4 Million Public Offering of Common Stock
34.8%
12/23 Soleno Therapeutics Inc (NASDAQ: SLNO) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $10.00 price target on the stock. 21.2%
11/27 Form 4 SOLENO THERAPEUTICS INC For: Nov 26 Filed by: Vivo Ventures Fund V, L.P. 18.5%
2/14 Form SC 13G/A SOLENO THERAPEUTICS INC Filed by: FEINBERG LARRY N 17.9%
10/2 Soleno Therapeutics Announces Positive Outcome from Second Planned Data Safety Monitoring Board Review of Phase III DESTINY PWS Clinical Trial of DCCR in Prader-Willi Syndrome 17.1%
1/21 Form S-8 SOLENO THERAPEUTICS INC 14.7%
12/9 Form SC 13D/A SOLENO THERAPEUTICS INC Filed by: Vivo Ventures V, LLC 10.7%
11/13 Q3/2019 9/30/2019 EPS 0.030 ZacksConsensus N/A ActVsEst N/A - N/A 10.0%
6/11 Form S-3 SOLENO THERAPEUTICS INC 9.5%
10/28 Form 4 SOLENO THERAPEUTICS INC For: Oct 24 Filed by: Vivo Ventures Fund V, L.P. 9.3%
12/23 Soleno Therapeutics Inc (NASDAQ: SLNO) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $10.00 price target on the stock. 21.2%
11/27 Form 4 SOLENO THERAPEUTICS INC For: Nov 26 Filed by: Vivo Ventures Fund V, L.P. 18.5%
2/14 Form SC 13G/A SOLENO THERAPEUTICS INC Filed by: FEINBERG LARRY N 17.9%
10/2 Soleno Therapeutics Announces Positive Outcome from Second Planned Data Safety Monitoring Board Review of Phase III DESTINY PWS Clinical Trial of DCCR in Prader-Willi Syndrome 17.1%
1/21 Form S-8 SOLENO THERAPEUTICS INC 14.7%
12/9 Form SC 13D/A SOLENO THERAPEUTICS INC Filed by: Vivo Ventures V, LLC 10.7%
11/13 Q3/2019 9/30/2019 EPS 0.030 ZacksConsensus N/A ActVsEst N/A - N/A 10.0%
6/11 Form S-3 SOLENO THERAPEUTICS INC 9.5%
10/28 Form 4 SOLENO THERAPEUTICS INC For: Oct 24 Filed by: Vivo Ventures Fund V, L.P. 9.3%
TOP News Decliners
3/12
Soleno Therapeutics Inc (NASDAQ: SLNO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.
-17.5%
8/3 Soleno Therapeutics Inc (NASDAQ: SLNO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.25 price target on the stock. -12.4%
12/26 Soleno Therapeutics Inc (NASDAQ: SLNO) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -10.7%
1/24 Form 4 SOLENO THERAPEUTICS INC For: Jan 23 Filed by: Yen Kristen -9.3%
7/25 Soleno Therapeutics Provides Update on Ongoing DESTINY PWS Phase III Trial of DCCR in Prader-Willi Syndrome -8.9%
3/11 Soleno Therapeutics to Present at the 30th Annual Oppenheimer Healthcare Conference -8.8%
3/4 Form 10-K SOLENO THERAPEUTICS INC For: Dec 31 -8.3%
2/22 Soleno Therapeutics Inc (NASDAQ: SLNO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.75 price target on the stock. -7.0%
8/21 Soleno Therapeutics Inc (NASDAQ: SLNO) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -6.8%
12/11 Soleno Therapeutics Inc (NASDAQ: SLNO) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -6.0%
8/3 Soleno Therapeutics Inc (NASDAQ: SLNO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.25 price target on the stock. -12.4%
12/26 Soleno Therapeutics Inc (NASDAQ: SLNO) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -10.7%
1/24 Form 4 SOLENO THERAPEUTICS INC For: Jan 23 Filed by: Yen Kristen -9.3%
7/25 Soleno Therapeutics Provides Update on Ongoing DESTINY PWS Phase III Trial of DCCR in Prader-Willi Syndrome -8.9%
3/11 Soleno Therapeutics to Present at the 30th Annual Oppenheimer Healthcare Conference -8.8%
3/4 Form 10-K SOLENO THERAPEUTICS INC For: Dec 31 -8.3%
2/22 Soleno Therapeutics Inc (NASDAQ: SLNO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.75 price target on the stock. -7.0%
8/21 Soleno Therapeutics Inc (NASDAQ: SLNO) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -6.8%
12/11 Soleno Therapeutics Inc (NASDAQ: SLNO) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -6.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: